We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
-4.22%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$16.9B
AUM Growth
-$2.13B
(-11%)
Cap. Flow
-$1.02B
Cap. Flow
% of AUM
-6.06%
Top 10 Holdings %
Top 10 Hldgs %
39.23%
Holding
1,372
New
74
Increased
459
Reduced
680
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$138M |
| 2 |
NVIDIA
NVDA
|
+$69.6M |
| 3 |
Synaptics
SYNA
|
+$37.7M |
| 4 |
Microchip Technology
MCHP
|
+$29.7M |
| 5 |
Lam Research
LRCX
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$184M |
| 2 |
iShares China Large-Cap ETF
FXI
|
+$170M |
| 3 |
XLNX
Xilinx Inc
XLNX
|
+$169M |
| 4 |
Apple
AAPL
|
+$131M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$110M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.16% |
| 2 | Financials | 15.03% |
| 3 | Energy | 6.15% |
| 4 | Healthcare | 5.33% |
| 5 | Consumer Discretionary | 2.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Bristol-Myers Squibb
BMY
$134B
| $5.33M | 0.03% |
72,968
-17,007
| -19% | -$1.14M |
|
377
Celldex Therapeutics
CLDX
$2.96B
| $5.32M | 0.03% |
156,252
+12,137
| +8% | +$388K |
|
|
UMPQ
378
DELISTED
Umpqua Holdings Corp
UMPQ
| $5.31M | 0.03% |
281,595
-9,564
| -3% | -$196K |
|
379
Kymera Therapeutics
KYMR
$8.25B
| $5.25M | 0.03% |
124,128
+28,352
| +30% | +$1.2M |
|
380
Prothena Corp
PRTA
$436M
| $5.25M | 0.03% |
143,547
+22,879
| +19% | +$825K |
|
381
Cytokinetics
CYTK
$10.4B
| $5.25M | 0.03% |
142,602
-3,466
| -2% | -$123K |
|
382
Assurant
AIZ
$14B
| $5.2M | 0.03% |
28,596
-1,380
| -5% | -$226K |
|
|
TPTX
383
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $5.18M | 0.03% |
193,126
+58,489
| +43% | +$1.97M |
|
384
Beam Therapeutics
BEAM
$2.67B
| $5.18M | 0.03% |
90,383
+16,604
| +23% | +$1.09M |
|
385
Agios Pharmaceuticals
AGIO
$1.82B
| $5.18M | 0.03% |
177,859
-413
| -0.2% | -$12.6K |
|
386
Allogene Therapeutics
ALLO
$635M
| $5.17M | 0.03% |
567,918
+272,539
| +92% | +$2.84M |
|
|
SWTX
387
DELISTED
SpringWorks Therapeutics
SWTX
| $5.13M | 0.03% |
90,829
+15,538
| +21% | +$889K |
|
388
Arcus Biosciences
RCUS
$3.47B
| $5.1M | 0.03% |
161,554
+35,236
| +28% | +$1.18M |
|
389
Relay Therapeutics
RLAY
$4.09B
| $5.1M | 0.03% |
170,274
-19,728
| -10% | -$479K |
|
390
Globe Life
GL
$14.3B
| $5.07M | 0.03% |
50,393
-2,442
| -5% | -$248K |
|
391
Northern Oil and Gas
NOG
$2.25B
| $5.06M | 0.03% |
179,478
-26,311
| -13% | -$645K |
|
|
VXRT
392
DELISTED
Vaxart
VXRT
| $5.02M | 0.03% |
996,455
+148,681
| +18% | +$753K |
|
393
Annaly Capital Management
NLY
$17.2B
| $5M | 0.03% |
177,719
-6,626
| -4% | -$197K |
|
|
AXON
394
Axon Enterprise
AXON
$46.4B
| $4.98M | 0.03% |
36,188
-5,756
| -14% | -$789K |
|
|
BLD
395
DELISTED
TopBuild
BLD
| $4.98M | 0.03% |
27,433
-6,675
| -20% | -$1.49M |
|
396
American Financial Group
AFG
$11.8B
| $4.97M | 0.03% |
34,118
-1,653
| -5% | -$225K |
|
|
BLDP
397
Ballard Power Systems
BLDP
$805M
| $4.94M | 0.03% |
424,263
+73,785
| +21% | +$786K |
|
398
Protagonist Therapeutics
PTGX
$8.51B
| $4.93M | 0.03% |
208,094
+42,322
| +26% | +$1.19M |
|
399
Clean Energy Fuels
CLNE
$410M
| $4.8M | 0.03% |
604,449
-389,533
| -39% | -$2.62M |
|
400
Expedia Group
EXPE
$35.8B
| $4.78M | 0.03% |
24,427
+331
| +1% | +$61.9K |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Rafferty Asset Management held 1,372 positions worth $16.9B, down 11% from $19B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Rafferty Asset Management withdrew a net $1.02B in Q1 2022, closing 155 positions and reducing 680 holdings. Its most notable exit was Xilinx Inc, an estimated $169M position sold in full.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 35% a quarter earlier, followed by Financials and Energy.
Against the trend, Rafferty Asset Management opened a new position in Synaptics worth $33.9M.
- Rafferty Asset Management's largest Q1 2022 buy was Synaptics: 170,061 shares worth $33.9M.
- Rafferty Asset Management added most to Advanced Micro Devices in Q1 2022, an estimated $138M increase.
- Rafferty Asset Management's biggest Q1 2022 reduction was iShares Russell 2000 ETF, cutting an estimated $184M.
- Rafferty Asset Management fully exited Xilinx Inc in Q1 2022, selling an estimated $169M.
- Rafferty Asset Management's ten largest holdings make up 39% of its $16.9B portfolio in Q1 2022.
- Rafferty Asset Management opened 74 new positions and closed 155 in Q1 2022.
- Rafferty Asset Management's portfolio value fell 11% quarter-over-quarter to $16.9B.
Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.